Inovio Pharmaceuticals Inc (INO)

[KR_redondo]

7th Vaccine & ISV Congress Sitges, Barcelon Spain
27-29 October 2013

Premier conference on vaccines and vaccination. The 7th Vaccine & ISV Congress will feature science and public health topics, from primary vaccine research and vaccine manufacturers, to governmental policy, safety and regulation. The Vaccine & ISV Congress has enjoyed an exciting history covering all aspects of vaccines since 2007. Over this time a wealth of knowledge has been presented, including talks from eminent scientists such as Stanley A. Plotkin, Rino Rappuoli, Ab Osterhaus, Walter A. Orenstein, Myron M. Levine, Adel Mahmoud and Gregory A. Poland

http://www.vaccinecongress.com/

Monday 28 October, 15:30-17:30

*Immunoadjuvant IL-33 enhances Human Papillomavirus 16 E6/E7-specific cell-mediated immunity and induced potent antitumor immunity
University of Pennsylvania, USA, 2Inovio Pharmaceuticals, Inc, USA



*Induction of potent CTL activity for cancer immunotherapy: Development of VGX-3100 for HPV associated cancers and hTERT DNA vaccine for solid tumors

J. Yan1, M.P. Morrow1, P. Pankhong2, T. Shin2, N. Obeng-Adjei2, J.N. Walters2, A.S. Khan1, M. Bagarazzi1, D.B. Weiner2, N.Y. Sardesai*1
1Inovio Pharmaceuticals, Inc., USA, 2University of Pennsylvnia, USA



HIV-1 Env DNA Vaccine Plus Protein Boost Delivered By EP Expands B- And T-Cell Responses And Neutralizing Phenotype in vivo (poster)
K. Muthumani1, K. Broderick2, N. Hutnick1, M. Wise1, J. Yan2, J. Mendoza2, C. Tingey1, S. Flingai1, N. Sardesai2, D. Weiner*1
1University of Pennsylvania School of Medicine, USA, 2Inovio Pharmaceuticals Inc, USA



Synthetic enhanced EP delivered Ig DNA vector drives biologically relevant Anti-HIV-1 envelope responses in Vivo
K. Muthumani1, S. Flingai1, M. Wise1, C. Tingey1, E. Reuschel1, K. Ugen2, D. Weiner*1
1Department of Pathology and Laboratory Medicine, USA, 2University of South Florida Morsani College of Medicine, USA


The co-delivery of esx multivalent TB DNA vaccines with electroporation induces potent immune responses
(poster)
D.O. Villarreal*, D.B. Weiner
University of Pennsylvania, USA


Inovio will be well represented at this conference